ND04869
LCL from B-Lymphocyte
Description:
ISCHEMIC STROKE
NDPT110 - ISCHEMIC STROKE, AFRICAN AMERICAN
|
Repository
|
NINDS Repository
|
| Subcollection |
Cerebrovascular Disease |
|
Biopsy Source
|
Peripheral vein
|
|
Cell Type
|
B-Lymphocyte
|
|
Tissue Type
|
Blood
|
|
Transformant
|
Epstein-Barr Virus
|
|
Sample Source
|
LCL from B-Lymphocyte
|
|
Race
|
Black/African American
|
|
Ethnicity
|
Not Hispanic/Latino
|
|
Country of Origin
|
USA
|
|
Family History
|
Y
|
|
Species
|
Homo sapiens
|
|
Common Name
|
Human
|
| Limdi NA, Brown TM, Yan Q, Thigpen JL, Shendre A, Liu N, Hill CE, Arnett DK, Beasley TM, Race influences warfarin dose changes associated with genetic factors Blood126:539-45 2015 |
| PubMed ID: 26024874 |
| |
| Limdi NA, Nolin TD, Booth SL, Centi A, Marques MB, Crowley MR, Allon M, Beasley TM, Influence of Kidney Function on Risk of Supratherapeutic International Normalized Ratio-Related Hemorrhage in Warfarin Users: A Prospective Cohort Study American journal of kidney diseases : the official journal of the National Kidney Foundation126:539-45 2014 |
| PubMed ID: 25468385 |
| |
| Limdi NA, Limdi MA, Cavallari L, Anderson AM, Crowley MR, Baird MF, Allon M, Beasley TM, Warfarin Dosing in Patients With Impaired Kidney Function American Journal of Kidney Diseases56(5):823-31 2010 |
| PubMed ID: 20709439 |
| |
| Limdi NA, Arnett DK, Goldstein JA, Beasley TM, McGwin G, Adler BK, Acton RT, Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans Pharmacogenomics9:511-26 2008 |
| PubMed ID: 18466099 |
| |
| Limdi NA, McGwin G, Goldstein JA, Beasley TM, Arnett DK, Adler BK, Baird MF, Acton RT, Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin Clinical pharmacology and therapeutics83:312-21 2007 |
| PubMed ID: 17653141 |
| Temperature |
37 C |
| Percent CO2 |
5% |
| Percent O2 |
AMBIENT |
| Medium |
Roswell Park Memorial Institute Medium 1640 with 2mM L-glutamine or equivalent |
| Serum |
15% fetal bovine serum Not Inactivated |
| Substrate |
None specified |
| Subcultivation Method |
dilution - add fresh medium |
| Supplement |
- |
|
|